Table 2.
Main Ongoing Clinical Trials of Anti-LAG-3 Agents Combined with ICIs
| Clinical Trial | Cancer Type | Treatment Line | Anti-LAG3 Agent | Immunotherapy | Phase |
|---|---|---|---|---|---|
| NCT03625323 | NSCLC | ≥1 | Eftilagimod alfa | Pembrolizumab | II |
| NCT01968109 | Advanced solid tumors | ≥2 | BMS-986,016 | Nivolumab | Ib/II |
| NCT02460224 | Advanced Malignancies | ≥2 | LAG525 | PDR001 (anti-PD-1 mAb) | I/II |
| NCT03684785 | Advanced solid tumors | ≥2 | Cavrotolimod | Pembrolizumab or cemiplimab | Ib/II |
| NCT03156114 | Advanced solid tumors | ≥2 | BI 754,111 | BI754091 (anti-PD-1 mAb) | I |
| NCT04140500 | Advanced solid tumors | ≥2 | RO7247669 (anti-PD-1-LAG-3 Bispecific mAb) | - | I |
| NCT03849469 | Advanced solid tumors | ≥2 | XmAb®22,841 | Pembrolizumab | I |
Abbreviations: NSCLC, non-small cell lung cancer; mAb, monoclonal antibody.